8,075 results on '"Taylor, Ian"'
Search Results
202. Introduction
203. Crime in Context
204. Fraudsters and Villains: The Private Temptations of Market Society
205. Crime in the Future(s) Market
206. Young People, Crime and Fear in Market Societies
207. Lethal Markets: The Legal and Illegal Economies in Firearms
208. The Ninth Transition: The Rise of Market Society
209. List of Contributors
210. Opening and Closing the 49th Parallel: Responses to Free Trade and to Trans-Border Crime in Canada since 1989 1
211. ‘I'm proud of what I achieved; I'm also ashamed of what I done’: a soccer coach's tale of sport, status, and criminal behaviour
212. High water mark in insurance
213. 'Dynamic scaling for three-dimensional information visualisation'
214. Footsteps created path to knighthood; Honoured - some famous, some unknown; Honouring the purposeful and useful
215. Ingenuity, leadership rewarded; Deloitte recognises business excellence and leadership in difficult times
216. Enabling applications on the Grid - A Gridlab overview
217. Study of bluff body flow fields and aeroelastic stability using a discrete vortex method
218. China's Foreign Policy towards Africa in the 1990s
219. TEACHING SEASONS
220. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV‐1 infection of macrophages
221. In silico and multi-dimensional functional interrogation of tissue Tregs reveals novel therapeutics for autoimmunity and inflammation
222. Stage‐specific drivers of Pacific hake (Merluccius productus) recruitment in the California Current Ecosystem
223. Professionalism and the Coverage of Protest: How an Ethos of Professionalism in Journalism Guided the Ways in Which Journalists Reported on an Anti-Trump Demonstration
224. Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
225. Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models
226. Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
227. Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
228. Supplementary Figure Legend from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
229. Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
230. Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
231. Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
232. Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
233. Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
234. Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
235. Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
236. Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
237. Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
238. Supplementary Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
239. Spermiogenesis alterations in the absence of CTCF revealed by single cell RNA sequencing
240. VLSI implants for skeletal muscle assistance to the heart
241. The Go Programming Language and Environment.
242. Consistent patterns of male mate preference in the laboratory and field
243. Africa After the China Boom
244. Dependency redux: why Africa is not rising
245. Web Deployment Using Atom
246. Web Services Deployment
247. BitTorrent
248. P2P Deployment Using Jxta
249. Distributed Object Deployment Using Jini
250. On the Horizon
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.